Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1148/radiol.2441060810
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Tables
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schaefer, N. G.
Right arrow Articles by Hany, T. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schaefer, N. G.
Right arrow Articles by Hany, T. F.
(Radiology 2007;244:257-262.)
© RSNA, 2007

Nuclear Medicine

Hodgkin Disease: Diagnostic Value of FDG PET/CT after First-Line Therapy—Is Biopsy of FDG-avid Lesions Still Needed?1

Niklaus G. Schaefer, MD, Christian Taverna, MD, Klaus Strobel, MD, Cathrin Wastl, Michael Kurrer, MD, and Thomas F. Hany, MD

1 From the Division of Nuclear Medicine, Department of Radiology (N.G.S., K.S., C.W., T.F.H.); Division of Medical Oncology, Department of Internal Medicine (N.G.S., C.T.); and Department of Pathology (M.K.), University Hospital Zurich, Raemistr 100, CH-8091 Zurich, Switzerland. Received May 11, 2006; revision requested June 23; revision received August 2; accepted September 7; final version accepted November 9. Address correspondence to N.G.S. (e-mail: niklaus.schaefer{at}usz.ch).

Purpose: To retrospectively determine the sensitivity and specificity of co-registered fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with Hodgkin lymphoma after first-line therapy, with use of clinical follow-up or biopsy results as the reference standard.

Materials and Methods: Informed consent was obtained for imaging and included consent to use patient data for research purposes. Institutional review board approval was obtained. Between May 2001 and July 2005, the data for all patients (n = 66) at the authors' institution with proved Hodgkin lymphoma after first-line therapy were retrospectively reviewed. PET/CT scans were evaluated for the presence of abnormal FDG uptake and residual masses after the end of treatment and at further follow-up. All patients with pathologic FDG lesions underwent surgical biopsy for histopathologic confirmation. All patients with negative PET/CT scans at follow-up were evaluated for disease-free survival.

Results: An FDG-avid lesion was detected at PET/CT in 27 of the 66 patients (mean age ± standard deviation, 33.0 years ± 12.2). Recurrence of Hodgkin lymphoma was confirmed with biopsy in 23 of the 27 patients. The mean maximum standardized uptake value (SUV) of the histopathologically proved lesions was 7.32 (±2.01). Four patients had false-positive findings at PET/CT: Biopsy revealed only inflammatory changes, and the mean maximum SUV was 7.30 (±2.53). Thirty-nine patients (mean age, 36.7 years ± 10.8) did not have FDG-avid lesions and remained free of disease after a mean clinical follow-up of 26.2 months (±12.5) (specificity, 91% [39 of 43 patients]; sensitivity, 100% [23 of 23 patients]). The presence of bulky disease (>5 cm) after the end of treatment was a significant predictor of recurrent disease (P < .05).

Conclusion: The authors conclude that FDG PET/CT can help exclude persistent and/or recurrent Hodgkin lymphoma after first-line therapy. Because of the false-positive results and the toxicity of salvage chemotherapy, including high-dose chemotherapy with autologous stem cell support, biopsy of the FDG-avid lesion is still needed.

Supplemental material: http://radiology.rsnajnls.org/cgi/content/full/244/1/257/DC1

© RSNA, 2007




This article has been cited by other articles:


Home page
 NEJMHome page
C. L.M. Olweny, J. L. Ziegler, R. J. Papac, V. Subbiah, C. Ferme, H. Eghbali, and M. Henry-Amar
Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease
N. Engl. J. Med., February 14, 2008; 358(7): 742 - 743.
[Full Text] [PDF]

Home page
 BloodHome page
T. C. Kwee, R. M. Kwee, and R. A. J. Nievelstein
Imaging in staging of malignant lymphoma: a systematic review
Blood, January 15, 2008; 111(2): 504 - 516.
[Abstract] [Full Text] [PDF]